Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|February 11, 2016

GRAM Completes Fourth FDA Inspection

GRAM completed a fourth FDA inspection of its parenteral manufacturing facility with no Form 483 observation issues.

Grand River Aseptic Manufacturing (GRAM) announced on Feb. 10, 2016 the competition of its fourth FDA inspection of its contract parenteral manufacturing facility in Grand Rapids, MI.

The seven-day inspection included a general GMP and a pre-approval inspection. FDA found GRAM to be in compliance with the current good manufacturing practices (cGMP) and passed pre-approval inspection, with no Form 483 observation issues. According to FDA, Form 483 is issued at the conclusion of inspections if the investigators discover violations of the Food Drug and Cosmetic Act and related acts.

GRAM is a parenteral contract manufacturing organization focused on cGMP manufacturing and new product development. The company specializes in preclinical, clinical, and commercial manufacturing.

Source: GRAM


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.